Current Trials

TR-01

Banking of Tissue and Establishing Continuous Cell Lines and Xenografts From Neoplasia

Study Chair: C. Patrick Reynolds, MD PhD
Cancer Center Director
Texas Tech University Health Sciences Center
3601 4th Street, Mailstop 9445
Lubbock, TX 79430-6540
Phone: 806-743-1558
Fax: 806-743-2990
Email: patrick.reynolds@ttuhsc.edu

Trial currently open at: Don and Sybil Harrington Cancer Center, University Medical Center, TTUHSC (Lubbock campus), Joe Arrington Cancer Center and The University of Texas Southwestern Medical Center, William Beaumont Army Medical Center.

SPOC-2010-002

Phase I Trial of Intravenous Fenretinide (4-HPR) plus Intravenous Safingol for Patients with Relapsed Malignancies

Study Chair: David E. Gerber, M.D.
Harold C. Simmons Cancer Center
Division of Hematology/Oncology
5323 Harry Hines Blvd., Mail Code 8852
Dallas, TX 75390-8852
Phone: 214-648-4180
Email: david.gerber@utsouthwestern.edu

Trial currently open at: Accrual temporarily suspended.

SPOC-2011-001

Phase I/II Trial of Fenretinide/LXS oral powder (NSC 374551) plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma

Study Chair: Jayanthi Lea, MD
The University of Texas Southwestern Medical Center
5323 Harry Hines Blvd
Dallas, TX 75390
Phone: 214-648-2621
Email: jayanthi.lea@utsouthwestern.edu

Trial currently open at: Study Closed to Accrual, Study has been completed.

SPOC-2012-001

Phase I Dose-Escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Study Co-Chair: Paul Harker-Murray, MD, PhD
Medical College of Wisconsin/Children's Hospital of Wisconsin
8701 Watertown Plank Road
MFRC3018
Milwaukee, WI 53226
Phone: 414-955-4170
Email: pharker@mcw.edu

Study Co-Chair: William Meyer, MD
University of Oklahoma Health Sciences Center
1200 Children's Ave, Suite 14500
Oklahoma City, OK 73104
Phone: 405-271-5311 ext 42545
Email: William-meyer@ouhsc.edu

Trial currently open at: Accrual to this study has been suspended while a study amendment is being implemented.

(Medical College of Wisconsin/Children's Hospital of Wisconsin, University of Oklahoma Health Sciences Center, UT Southwestern Medical Center, TTUHSC Lubbock/University Medical Center and Cincinnati Children's Hospital.)

SPOC-2015-01

Phase 1 trial of dose escalated BGB324 in combination with docetaxel for previously treated advanced non-small cell lung cancer (NSCLC)

Study Chair: David E. Gerber, M.D.
Harold C. Simmons Cancer Center
Division of Hematology/Oncology
5323 Harry Hines Blvd., Mail Code 8852
Dallas, TX 75390-8852
Phone: 214-648-4180
Email: david.gerber@utsouthwestern.edu

Trial currently open at: The University of Texas Southwestern Medical Center

© South Plains Oncology Consortium (2008-2020)